The relation between plasma concentrations and properties of lorazepam administered orally as premedication was studied in patients undergoing minor surgery. The drug was found to be reliably absorbed in most subjects producing plasma concentrations similar to those reported after injection. Effective concentrations were obtained within 30-60 min, maintained for 4-6 h and were closely related to the action of the drug on memory and its sedative and anxiolytic properties. Its kinetics were described in about half the subjects by a one-compartment model, but in others two compartments were required. Variable half-lives were found (range 9.3-32.1 h, mean about 20 h). Sufficient drug remains after 24 h to suggest that residua] c.n.s. effects may still be present.
and female patients undergoing minor surgery and two volunteers were studied under the same ward conditions after informed consent was obtained (table I) . Measurements of blood concentrations were made in subjects 1-9 only. No subject had received any drugs over the previous 24 h and all had fasted from midnight. Lorazepam 50 ug kg ~ ' was administered orally approximately 6h before surgery. Blood samples were obtained at 0, 0.5, 1, 1.5, 2 h and then hourly for 6h. Subjects were either sitting or lying down during this period. Further samples were taken at 9,24,33, and 48 h after drug administration or as near these times as convenient. The samples were centrifuged and the plasma deep frozen until the concentration of lorazepam was determined by gas-liquid chromatography (GLC).
GLC assay for lorazepam. A method similar to that described by Greenblatt, Franke and Shader (1978) was used, but the chromatograph was a Pye-Unicam Model 104 equipped with a nickel-63 electron capture detector and the carrier gas was nitrogen 40mlmin~'. Column temperature was 270 °C. Stock solutions of oxazepam (internal standard) and lorazepam were prepared in toluene. Peaks corresponding to the re-arranged forms of lorazepam and the internal standard oxazepam had retention times of 3.8 and 3.0 min respectively. An additional peak was sometimes observed in plasma samples left for a few hours at room temperature before extraction. Samples were therefore immediately deep-frozen after collection.
Plasma samples (lml) to which internal standard (50 ng) had been added, were extracted once with benzene 5ml containing 1.5% isoamyl alcohol. A 4-ml aliquot of the organic phase was evaporated to dryness and the residue redissolved in toluene 50ulitre containing 15% isoamyl alcohol before injection (0.5 ulitre). Five calibration standards (10-50 ng ml ~ ') were analysed with each set of unknown samples. The slope of the calibration curve varied by approximately 25% over a period of about 3 months, but was much less for assays carried out within a weekly period and the precision was similar to that reported by Greenblatt and his co-workers. In plasma samples containing less than lOngml" ', the precision and accuracy of the assay was less. Results reported are the mean of duplicated determinations.
Pharmacokinetic analysis. The drug concentrations in each individual were fitted to either a one-compartment or a two-compartment pharmacokinetic model by computer, using least squares regression analysis.
Clinical study
A number of tests were carried out concurrent with the sampling of blood in the same subjects (1-9) and in six others (subjects 10-15), over a 6-h period after drug administration or until the patients underwent operation. Retrograde and anterograde amnesia were measured by showing the subject a different postcard-size coloured picture of everyday objects such as a house, keys or a tree selected in the same order for each subject, but avoiding any collusion between them. This avoided any possibility that some objects may be more readily remembered than others. At 24 h after drug administration, subjects were asked to recall these pictures. Those which had been forgotten were mixed with another group of cards, similar in colouring and dimension, and the subjects were then asked to recognize any they had seen before. The number of subjects recalling at each time and numbers either recalling or recognizing the cards were recorded. Short term recall was measured by asking the subjects to name a playing card seen and then to recall it 5 min later. Sedation was measured on a five-point scale: 1 being no sedation, 5 being so sedated that the patient could not be aroused by gentle shaking. The grading criteria were the same as those used by Pandit, Heisterkamp and Cohen (1976) . Anxiety was measured by asking the subjects to estimate and mark a 10-cm visual analog scale in the range "calm" to "nervous". This test was omitted by the two volunteers since they were not undergoing operation. Judgement of time. All subjects were asked to estimate a 10-s time interval and the estimate recorded.
The results of the clinical tests were analysed by the Mann-Whitney U Test (amnesia and sedation), Chi-square test (short-term recall) and paired t test (anxiety). Table II shows the plasma lorazepam concentrations in all nine subjects. Absorption of the drug in most cases was rapid so that plasma concentrations generally exceeded 30ngml~' after 30 min and peak concentrations were attained within 90 min. Subject 1, however, had much slower absorption characteristics. The drug concentration did not peak until about 5 h and a significant time-lag was observed before absorption commenced. A timelag was found in subject 7, although absorption was subsequently rapid. Table III shows the halflives from the computer-fitting process for all nine subjects. Data from five of the subjects fitted onecompartment kinetics and data from four, two compartments.
RESULTS
The results of the clinical tests are shown in table IV. The ability of the patients and volunteers to recall memory cards after 24 h was greatly reduced between 1-5 h after drug administration, the effect being greatest at 2h. Even when the patients were asked to recognize the picture cards, there was still significant reduction of memory at these times. Short-term recall of the playing cards was also reduced between 1 and 5h. Sedation scores increased over the same period and anxiety was significantly reduced, even at 6h following administration. Estimates of the lO^s time interval were variable, eight subjects showing an increase and six a decrease. The average results are shown in table IV, but the differences are not significant.
From the data obtained, a relationship between plasma lorazepam concentrations and clinical ef- fects was demonstrated. Plasma concentrations in each individual patient were calculated from the computer results for each time at which clinical data had been obtained. Using these best estimates of plasma concentration, the results were analysed in groups at 10-ngml" 1 intervals in the range 0-50ngml" '. The relation between plasma lorazepam concentration and its amnesic, sedative and anxiolytic effects is shown in figure 1 . The effects of lorazepam were maximum at plasma concentrations of 30-50 ng ml" 1 while, at less than lOngml" ', there was little action of the drug. 
DISCUSSION
The mean peak concentration observed after adjusting the dose for body weight was 42.2 ng ml" '. This is in close agreement with the values of 45.8 and 39.0 ng ml" ' calculated by a similar procedure from the results obtained by Greenblatt and others (1979) using 2-mg and 4-mg doses. However, although some individual variation in blood concentrations is evident in our results (table II) , it is considerably less marked than in the study reported by Dundee and others (1978) . They also observed that plasma concentrations after oral administration were less than after equal doses administered i.m. and that there was no significant difference in mean plasma concentrations after 2-mg and 4-mg doses. Our study showed that some patients had slower absorption characteristics than others. It is uncertain whether the slower absorption shown by subject 1 was caused by physiological factors, differences in release of the drug from individual tablets, a combination of these factors, or other causes. In general, our results obtained with patients are consistent with previously published findings observed in volunteers (Greenblatt et al., 1979) . Compared with lorazepam, diazepam and some other benzodiazepines show a more marked multicompartment character. Elimination halflives for lorazepam (table III) range from 9.3 to 32.1 h (mean about 20 h), which is greater than the 16 h reported by Greenblatt and others (1979) in volunteers. Both figures are greater than earlier reports (Elliott, 1976; Greenblatt etal., 1976) . The concentration of lorazepam remaining in the plasma after 24 h (mean 14 ng ml ~ ') is comparable to the value of 21 ng ml ~ ' reported by Dundee and others (1979) .
The effect of oral lorazepam on long-term memory was striking, with maximum failure to recall the pictures between 1-5 h after administration. Retrograde amnesia did not occur. Anterograde amnesia, although slightly slower in onset, was similar to that caused by the injection of 4-mg doses i.v. (Dundee and George, 1976; Pandit, Heisterkamp and Cohen, 1976) . The short-term recall of playing cards at zero time was complete, but by 1 h was reduced to about 30%. The maximum effect occurred after 3h. Sedation scores paralleled the effect on memory. No patient was unrousable, but at the times of maximum effect, the subjects had to be shaken vigorously to answer questions and participate in the tests. Since the assessment procedure adopted in this study was identical to that described and used by Pandit, Heisterkamp and Cohen (1976) , it is possible to compare directly the sedative effects of 4-mg doses i.v. used in their study with the smaller doses administered orally in this investigation. The onset of sedation following administration i.v. is more rapid, but the depth of sedation and duration of action are similar. These observations provide evidence that the oral administration of lorazepam is as effective as i.v. administration in similar doses.
The results of this study confirm previous clinical experience with the drug. It is reliably absorbed after oral administration and is clinically effective for 1-5 h, which makes it particularly useful for premedication of all patients on an operating list at one time. The pharmacokinetic calculations show that lorazepam has a half-life of 9-32 h and that the average plasma concentration after 24 h is 14ngml~ '. Therefore, if patients are discharged from hospital less than 24 h after administration, the blood concentrations of lorazepam may in some cases still produce sedative and amnesic effects. They must return home accompanied and avoid additional c.n.s. depressant drugs such as alcohol.
The study also confirms that lorazepam has not only prolonged sedative effects which are greater than those of diazepam, but also produces intense amnesia. The amnesic effects are useful for unpleasant procedures such as gastroscopy, sigmoidoscopy and the emergent delirium of ketamine (Dundee and Lilburn, 1978 
SUMAWO
Se estudio la relacion cntre las concentraciones en el plasma y las propiedades del lorazepam, administrado por via oral cuaj premedicacion, en pacientes bajo tratamiento quirurjico menor. Se encontro que en la mayoria de los sujetos la droga era absorbida perfectamente, produciendo concentraciones en el plasma similares a las descritas despues de la inyeccion. Se obtu vieron concentraciones efectivas en el plazo de 30 a 60 min, sc mantuvicron de 4 a 6h y estuvieron extrechamente relacionadas con la acti vidad de la droga en la memoria y con sus propiedades sedanvas y anxioliticas. Sus aspectos cineticos se describieron en, aproximadamente, la mitad de los sujetos mediante el modelo de un compartimento, pero en otros fue necesario el modelo de dos compartimentos. Se enconrxaron vidas medias variables (gama de 93-32,1 h; media de 20 h aproximadamente). Despues de 24 h aim queda suficiente cantidad de droga como para sugerir que los efectos residuales en el sistema nervioso central estan aim presentes.
